Overview

A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence

Status:
NOT_YET_RECRUITING
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This study aims to compare the safety and tolerability of cadonilimab applied after curative hepatectomy for hepatocellular carcinoma combined with high - risk recurrent factors.
Phase:
PHASE2
Details
Lead Sponsor:
Guangxi Medical University